IGT once again empowers clients' cell research: CAR-NK therapy brings new hope for the treatment of systemic sclerosis.

Systemic sclerosis (SSc) is a progressive autoimmune disease characterized by immune dysregulation, microvascular dysfunction, and extensive skin fibrosis.

On June 24, 2025, Professor Xu Huji's team from Changzheng Hospital, Naval Medical University published a paper entitled An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis in Cell. The research team successfully treated a patient with diffuse cutaneous systemic sclerosis (dcSSc) using induced pluripotent stem cell (iPSC)-derived CD19/BCMA dual-target CAR-NK therapy (QN-139b). Employing cutting-edge technologies such as single-cell RNA sequencing, spatial transcriptomics analysis, whole-exome sequencing, and proteomics, the team comprehensively analyzed the mechanism of action of QN-139b and revealed its key immunomodulatory role in reversing disease progression.

The results showed that this therapy can significantly deplete pathogenic B cells, reduce autoantibody levels, alleviate skin and organ fibrosis, and improve vascular function. These findings provide new insights for clinical diagnosis and treatment, and also open up new directions for the management of autoimmune diseases. In this systematic multi-omics study, IGT® was honored to provide high-quality reagents (AIExome human exome Panel V3) required for exome capture and related rna sequencing services.

Original link: https://doi.org/10.1016/j.cell.2025.05.038

IGT Product Advantages

Relying on the independently developed TargetSeq® hybrid capture sequencing technology and IGT® Oligo Pools large-scale parallel synthesis platform, IGT can quickly provide various high-quality predefined and customized products, covering comprehensive solutions from probe design to kit delivery, so as to meet different scientific research and clinical needs.